ERG and prostate cancer: Treatment of prostate cancer cells with the USP9X inhibitor WP1130 resulted in ERG degradation both in vivo and in vitro, impaired the expression of genes enriched in ERG and prostate cancer relevant gene signatures, and inhibited growth of ERG-positive tumors in mouse xenograft models (Wang et al., 2014).